Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
Rhea-AI Summary
Senti Biosciences (Nasdaq: SNTI) announced that Dr. Timothy Lu, co-founder and CEO, will serve as a panelist at Biotech Showcase 2026 in San Francisco, taking place January 12–14, 2026. The panel, titled "Engineering the Future: Advances in Cell and Gene Therapies", is scheduled for Tuesday, January 13, 2026 at 8:00 AM PST in Workshop 1 (Yosemite A).
The session features industry leaders from pharmaphorum, Diakonos Oncology, Opus Genetics, IN8bio, and Epicrispr Biotechnologies and will discuss advances in cell and gene therapies using technologies such as gene circuits. Investors can view session details on the conference website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SNTI gained 2.78%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.7% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $825K to the company's valuation, bringing the market cap to $30M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SNTI was down 6.09% while peers showed mixed moves: LSB down 20.62%, LVTX down 3.87%, MRSN up 0.62%, IPSC up 10.97%, and MURA flat. The lack of a consistent direction across peers points to a stock-specific context rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Inducement grants | Neutral | +2.6% | New-hire stock options under inducement plan with limited disclosed financial impact. |
| Dec 09 | Regulatory designation | Positive | -35.6% | FDA RMAT designation for SENTI-202 in relapsed or refractory AML. |
| Dec 09 | Clinical data update | Positive | -35.6% | Updated Phase 1 SENTI-202 data showing strong ORR, CR/CRh, and MRD negativity. |
| Dec 04 | Conference/webcast notice | Neutral | +0.9% | Announcement of ASH webcast to review updated SENTI-202 clinical data. |
| Nov 13 | Earnings and pipeline | Negative | -5.3% | Q3 2025 loss, low cash of <b>$12.2M</b>, and upcoming SENTI-202 readout confirmation. |
Positive clinical and regulatory news has previously coincided with negative price reactions, while earnings-related downside and routine items tended to align more with modest declines or small gains.
Over the last few months, SNTI reported Q3 2025 results with a $18.1M net loss and highlighted going-concern risks, which coincided with a -5.29% move. The company then focused on SENTI-202, presenting Phase 1 data with 50% ORR, up to 42% CR/CRh, and a 7.6‑month median remission, and received FDA RMAT designation, yet the stock fell 35.56%. Routine items like conference/webcast notices and inducement grants saw small positive reactions. Today’s conference participation fits this pattern of non-fundamental communication alongside a pressured share price.
Market Pulse Summary
This announcement highlights Senti Bio’s participation in a Biotech Showcase 2026 panel on cell and gene therapies on January 13, 2026 at 8:00 AM PST. It underscores ongoing visibility for the Gene Circuit platform rather than providing new clinical or financial data. In context of recent RMAT designation, Phase 1 SENTI-202 results, and earlier going-concern disclosures, investors may watch for future updates that directly address funding and trial progress.
Key Terms
cell and gene therapies medical
AI-generated analysis. Not financial advice.
Live panel presentation on Tuesday, January 13th at 8:00 AM PT
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Dr. Timothy Lu, Co-Founder and CEO, will participate as a panelist alongside Jonah Comstock, Editor in Chief, pharmaphorum; Jay Hartenbach, President & COO, Diakonos Oncology; George Magrath CEO, Opus Genetics; Kate Rochlin COO, IN8bio; and Amber Salzman CEO, Epicrispr Biotechnologies at Biotech Showcase 2026, taking place January 12–14, 2026, in San Francisco, CA.
Panel presentation details are as follows:
Title: Engineering the Future: Advances in Cell and Gene Therapies
Date/Time: Tuesday, January 13, 2026 at 8:00 AM PST
Location: Workshop 1 (Yosemite A)
For more information, please visit the conference website here.
About Biotech Showcase
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 17th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-
to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
When will Senti Biosciences (SNTI) present at Biotech Showcase 2026?
What is the title of the SNTI-related panel at Biotech Showcase 2026?
Where is the Senti Biosciences panel located at the conference?
Who are the other panelists joining SNTI CEO Dr. Timothy Lu on January 13, 2026?
Will the SNTI panel discuss the company's Gene Circuit platform?
